Trident Lifeline
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Trident Lifeline's board approved the issuance of 12,22,200 equity shares at Rs336.60 each aggregating about Rs41.14 crore to public investors and 5,00,400 fully convertible warrants at the same price aggregating about Rs16.84 crore to promoter-group and other investors, subject to shareholder approval. The warrants were convertible into one equity share each within 18 months with 25% payable on allotment and the balance on exercise, and the board convened an extraordinary general meeting on 27 October 2026 alongside an amendment to the articles to enable warrant issuance. The company held a 59.67% stake in Trident Mediquip, a medical-device maker, after acquiring an additional 1% holding for about Rs95.40 lakh in cash on 30 September 2026. Trident Mediquip reported turnover of Rs27.31 crore in FY26, against Rs21.29 crore in FY25 and Rs20.58 crore in FY24.
Powered by Tijori
Trident Lifeline's board approved the issuance of 12,22,200 equity shares at Rs336.60 each aggregating about Rs41.14 crore to public investors and 5,00,400 fully convertible warrants at the same price aggregating about Rs16.84 crore to promoter-group and other investors, subject to shareholder approval. The warrants were convertible into one equity share each within 18 months with 25% payable on allotment and the balance on exercise, and the board convened an extraordinary general meeting on 27 October 2026 alongside an amendment to the articles to enable warrant issuance. The company held a 59.67% stake in Trident Mediquip, a medical-device maker, after acquiring an additional 1% holding for about Rs95.40 lakh in cash on 30 September 2026. Trident Mediquip reported turnover of Rs27.31 crore in FY26, against Rs21.29 crore in FY25 and Rs20.58 crore in FY24.
Powered by Tijori
Trident Lifeline's board approved a preferential issue of 12,22,200 equity shares at Rs 336.60 each aggregating Rs 41.14 crore to public investors and 5,00,400 fully convertible warrants at the same price aggregating Rs 16.84 crore to promoter group and public investors, subject to approval at an extraordinary general meeting on 27 October 2026. Each warrant was convertible into one equity share within 18 months with 25% payable on allotment and the balance on exercise, and the board also approved an amendment to the articles to enable warrant issuance and appointed NSDL for remote e-voting. The company held a 59.67% stake in Trident Mediquip, a medical-device maker in India with turnover of Rs 27.31 crore in FY26. That holding was raised from 58.67% on 30 September 2026 through a 1.00% purchase for about Rs 95.40 lakh in cash. Trident Mediquip was incorporated in October 2019 with authorised capital of Rs 11.00 crore and paid-up capital of Rs 10.00 crore, and reported turnover of Rs 20.58 crore in FY24 and Rs 21.29 crore in FY25.
Powered by Tijori
Trident Lifeline's board approved a preferential issue of 12,22,200 equity shares at Rs 336.60 each aggregating Rs 41.14 crore to public investors and 5,00,400 fully convertible warrants at the same price aggregating Rs 16.84 crore to promoter group and public investors, subject to approval at an extraordinary general meeting on 27 October 2026. Each warrant was convertible into one equity share within 18 months with 25% payable on allotment and the balance on exercise, and the board also approved an amendment to the articles to enable warrant issuance and appointed NSDL for remote e-voting. The company held a 59.67% stake in Trident Mediquip, a medical-device maker in India with turnover of Rs 27.31 crore in FY26. That holding was raised from 58.67% on 30 September 2026 through a 1.00% purchase for about Rs 95.40 lakh in cash. Trident Mediquip was incorporated in October 2019 with authorised capital of Rs 11.00 crore and paid-up capital of Rs 10.00 crore, and reported turnover of Rs 20.58 crore in FY24 and Rs 21.29 crore in FY25.
Powered by Tijori
Trident Lifeline's board on Saturday approved the migration of the company's equity shares from the SME platform of BSE to the main boards of BSE and NSE, subject to approvals from shareholders, the stock exchanges, and other authorities. The board also appointed Ms. Smita Kiran Davda and Mr. Sachin Bhandari as additional non-executive independent directors for five-year terms, pending shareholder ratification. Ms. Davda is a fellow chartered accountant with senior leadership experience at Yes Bank, while Mr. Bhandari brings pharmaceutical industry expertise from roles at UCB Pharma, Boehringer Ingelheim, and Sun Pharma. The company fixed June 5, 2026, as the cut-off date for determining shareholder eligibility for the postal ballot on the resolutions. NSDL has been appointed as the remote e-voting agency, and M/s. Mittal V Kothari & Associates as the scrutinizer for the postal ballot process.
Powered by Tijori
Trident Lifeline's board on Saturday approved the migration of the company's equity shares from the SME platform of BSE to the main boards of BSE and NSE, subject to approvals from shareholders, the stock exchanges, and other authorities. The board also appointed Ms. Smita Kiran Davda and Mr. Sachin Bhandari as additional non-executive independent directors for five-year terms, pending shareholder ratification. Ms. Davda is a fellow chartered accountant with senior leadership experience at Yes Bank, while Mr. Bhandari brings pharmaceutical industry expertise from roles at UCB Pharma, Boehringer Ingelheim, and Sun Pharma. The company fixed June 5, 2026, as the cut-off date for determining shareholder eligibility for the postal ballot on the resolutions. NSDL has been appointed as the remote e-voting agency, and M/s. Mittal V Kothari & Associates as the scrutinizer for the postal ballot process.
Powered by Tijori
Jan 1 (Reuters) - Trident Lifeline Ltd TIDT.BO:
BUYS ADDITIONAL 9.04% STAKE IN TRIDENT MEDIQUIP
COST OF ACQUISITION ABOUT 44.2 MILLION RUPEES
Source text: ID:nBSE1MxqYX
Further company coverage: TIDT.BO
(([email protected];))
Jan 1 (Reuters) - Trident Lifeline Ltd TIDT.BO:
BUYS ADDITIONAL 9.04% STAKE IN TRIDENT MEDIQUIP
COST OF ACQUISITION ABOUT 44.2 MILLION RUPEES
Source text: ID:nBSE1MxqYX
Further company coverage: TIDT.BO
(([email protected];))
April 16 (Reuters) - Trident Lifeline Ltd TIDT.BO:
APPROVED ISSUE OF 999,000 FULLY CONVERTIBLE WARRANTS
WARRANTS CONVERTIBLE AT 266 RUPEES EACH
Source text: ID:nBSEc0fdVL
Further company coverage: TIDT.BO
(([email protected];;))
April 16 (Reuters) - Trident Lifeline Ltd TIDT.BO:
APPROVED ISSUE OF 999,000 FULLY CONVERTIBLE WARRANTS
WARRANTS CONVERTIBLE AT 266 RUPEES EACH
Source text: ID:nBSEc0fdVL
Further company coverage: TIDT.BO
(([email protected];;))
April 9 (Reuters) - Trident Lifeline Ltd TIDT.BO:
TO CONSIDER FUND RAISING
Source text: ID:nBSE3bZbd
Further company coverage: TIDT.BO
(([email protected];;))
April 9 (Reuters) - Trident Lifeline Ltd TIDT.BO:
TO CONSIDER FUND RAISING
Source text: ID:nBSE3bZbd
Further company coverage: TIDT.BO
(([email protected];;))
July 17 (Reuters) - Trident Lifeline Ltd TIDT.BO:
NAMES ASHISH ANANDSINGH BAFNA AS CFO
Source text for Eikon: ID:nBSE6zhZKQ
Further company coverage: TIDT.BO
(([email protected];;))
July 17 (Reuters) - Trident Lifeline Ltd TIDT.BO:
NAMES ASHISH ANANDSINGH BAFNA AS CFO
Source text for Eikon: ID:nBSE6zhZKQ
Further company coverage: TIDT.BO
(([email protected];;))
Trident Lifeline Ltd TIDT.BO:
TRIDENT LIFELINE LTD- RECEIVED LETTER FROM AGRICULTURE DEPARTMENT TO CLOSE CORPORATE OFFICE IN APMC
TRIDENT LIFELINE LTD- TO FILE AN APPEAL
Source text for Eikon: ID:nBSE2gqw0l
Further company coverage: TIDT.BO
Trident Lifeline Ltd TIDT.BO:
TRIDENT LIFELINE LTD- RECEIVED LETTER FROM AGRICULTURE DEPARTMENT TO CLOSE CORPORATE OFFICE IN APMC
TRIDENT LIFELINE LTD- TO FILE AN APPEAL
Source text for Eikon: ID:nBSE2gqw0l
Further company coverage: TIDT.BO
Dec 11 (Reuters) - Trident Lifeline Ltd TIDT.BO:
APPROVED TO SUBSCRIBE 51.00% EQUITY SHARES OF 10 RUPEES EACH OF PROPOSED CO TLL PARENTERALS
Further company coverage: TIDT.BO
(([email protected];))
Dec 11 (Reuters) - Trident Lifeline Ltd TIDT.BO:
APPROVED TO SUBSCRIBE 51.00% EQUITY SHARES OF 10 RUPEES EACH OF PROPOSED CO TLL PARENTERALS
Further company coverage: TIDT.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Trident Lifeline do?
Trident Lifeline Limited is a pharmaceutical company that focuses on ethical marketing of a variety of products domestically and internationally through a third-party network spanning multiple countries around the world.
Who are the competitors of Trident Lifeline?
Trident Lifeline major competitors are Shivalik Rasayan, Prevest Denpro, Albert David, Jenburkt Pharma, Medicamen Biotech, Wanbury, Zim Laboratories. Market Cap of Trident Lifeline is ₹506 Crs. While the median market cap of its peers are ₹478 Crs.
Is Trident Lifeline financially stable compared to its competitors?
Trident Lifeline seems to be less financially stable compared to its competitors. Altman Z score of Trident Lifeline is 3.8 and is ranked 4 out of its 8 competitors.
Does Trident Lifeline pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Trident Lifeline latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Trident Lifeline allocated its funds?
Companies resources are allocated to majorly unproductive assets like Accounts Receivable
How strong is Trident Lifeline balance sheet?
Balance sheet of Trident Lifeline is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Trident Lifeline improving?
Yes, profit is increasing. The profit of Trident Lifeline is ₹21.4 Crs for TTM, ₹19.04 Crs for Mar 2026 and ₹11.75 Crs for Mar 2025.
Is the debt of Trident Lifeline increasing or decreasing?
Yes, The net debt of Trident Lifeline is increasing. Latest net debt of Trident Lifeline is ₹85.75 Crs as of Sep-26. This is greater than Mar-26 when it was ₹64.61 Crs.
Is Trident Lifeline stock expensive?
Trident Lifeline is not expensive. Latest PE of Trident Lifeline is 26.58, while 3 year average PE is 38.69. Also latest EV/EBITDA of Trident Lifeline is 18.61 while 3yr average is 31.88.
Has the share price of Trident Lifeline grown faster than its competition?
Trident Lifeline has given better returns compared to its competitors. Trident Lifeline has grown at ~34.27% over the last 4yrs while peers have grown at a median rate of 8.86%
Is the promoter bullish about Trident Lifeline?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Trident Lifeline is 62.46% and last quarter promoter holding is 62.59%. Please check if dilutions happened via QIP/ Offerings etc.
Are mutual funds buying/selling Trident Lifeline?
There is Insufficient data to gauge this.